Fifteen world-renowned leaders in hematology and oncology whose research has improved and extended the lives of millions of patients make up the 2019 class of Giants of Cancer Care® award winners.
Fifteen world-renowned leaders in hematology and oncology whose research has improved and extended the lives of millions of patients make up the 2019 class of Giants of Cancer Care® award winners. This year's recipients include physician—scientists who conducted groundbreaking clinical trials, made important discoveries in cancer genetics, and are developing cutting-edge therapeutics to provide personalized patient care.
The 2019 Giants of Cancer Care® award winners and their respective categories are:
The winners are scheduled to be honored at a ceremony on May 30, 2019, at the Adler Planetarium in Chicago, Illinois.
The award recipients were chosen from a field of more than 600 clinicians and investigators, a record number of nominees that represents a 16% increase over 2018. This year's roster included a record-high 64 international candidates from 25 countries.
Each member of the 2019 class has been deemed by his or her peers to be a person who challenges the conventional wisdom with innovative, even revolutionary, contributions to clinical research, translational care, and/or patient care.
A 7-member advisory board winnowed the nominees down to 75 finalists, all of whom would have been worthy recipients. An elite selection committee of hematologists and oncologists then voted to choose the winners.
"The nominees truly represent a remarkably talented and accomplished group of biomedical scientists and physicians with a deep-seated expertise and impact in the field of cancer care," said George D. Demetri, MD, a 2014 Giants of Cancer Care® award winner in the gastrointestinal cancer category, who chaired this year's advisory board. "All of us on the steering committee give our heartfelt congratulations and utmost respect to these talented and committed individuals who make up this year's class of Giants of Cancer Care®."
Demetri is a professor of medicine at Harvard Medical School, co-director of the Ludwig Center at Harvard, and senior vice president for Experimental Therapeutics at Dana-Farber Cancer Institute.Demetri stressed the impact that the Giants of Cancer Care® have had on patients and their families. "The work of these honorees has touched the lives, and even saved the lives, of hundreds of thousands of cancer patients worldwide, changing practice for the better and improving our care of patients with many different forms of the disease we call cancer, he said. "It is a testament to the power of research and to the hard work of these individuals and to the commitment of the United States and other countries, as well as the institutions that have supported and enabled their work."
The peer review and peer voting processes, Demetri added, make this award particularly meaningful because the winners know their efforts have generated interest and respect from cancer professionals around the world.
OncLive began the Giants of Cancer Care® program in 2013 to honor clinicians and investigators who have contributed to advancements in the understanding of cancer and the treatment of patients. Recipients must possess selflessness, compassion for patients, and a desire to understand and develop life-changing anticancer treatments.
This year’s class brings the total number of honorees recognized through the program to 98.
"Now in its seventh year of issuing the Giants of Cancer Care® awards, the program has grown bigger and better than we ever expected," said Michael J. Hennessy, Jr., president of MJH Associates, Inc, parent company of OncLive®. "This year's winners represent a group of incredibly talented and accomplished scientists and physicians whose impact on cancer research and treatment is truly beyond measure. We are honored to call them Giants of Cancer Care."
Eric P. Winer, MD, has designed and conducted clinical trials that have changed clinical practice and paved the way toward more personalized treatment of patients with breast cancer.
Director, Breast Oncology Center, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute
Charles M. Perou, PhD, conducts research across cancer biology, genomics, genetics, bioinformatics, statistics, systems biology, and clinical practice.
The May Goldman Shaw Distinguished Professor of Molecular Oncology, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center
Richard Pazdur, MD, is founding director of the Oncology Center of Excellence, whose mission is to harness the combined skills of FDA experts to accelerate the development of novel cancer products.
Director, FDA Oncology Center of Excellence
The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco (UCSF) and the Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center
Alan P. Venook, MD, is a nationally recognized expert in colorectal and liver cancers who served as the founding chair of the National Cancer Institute’s Hepatobiliary Task Force.
Bernard J. Escudier, MD, has been instrumental in the development of many new therapies for patients with renal cell carcinoma (RCC), including immunotherapies and targeted therapies.
Chair of the Renal Cancer Unit, Institut Gustave Roussy, Villejuif, France
Beth Y. Karlan, MD, has dedicated her career to improving cancer care for women by accelerating translation of scientific discoveries to the bedside, shaping current standards of care, and training the next generation of physician/scientists.
Vice Chair of Women’s Health Research and Director of Cancer Population Genetics at the David Geffen School of Medicine, University of California, Los Angeles (UCLA)
Frederick R. Appelbaum, MD, is internationally known for his work in the development of transformative therapies for leukemias, lymphomas, and other blood cancers.
Executive Vice President and Deputy Director at Fred Hutchinson Cancer Research Center (Fred Hutch)
David H. Johnson, MD, is a leader in lung cancer research whose work spans clinical investigations in targeted therapies, chemotherapy, radiation therapy, and oncogenic mutations.
Donald W. Seldin Distinguished Chair in Internal Medicine, University of Texas (UT) Southwestern Medical Center
Saul A. Rosenberg, MD, is a pioneer in the use of curative chemoradiation to treat patients with Hodgkin lymphoma and helped launch the medical oncology field at Stanford.
Maureen Lyles D’Ambrogio Professor Emeritus, Stanford School of Medicine
F. Stephen Hodi, MD, is a trailblazer in the development of immunotherapy and melanoma therapeutics, particularly checkpoint inhibitors.
Director of the Center for Immuno-Oncology and the Melanoma Center at Dana-Farber Cancer Institute
S. Vincent Rajkumar, MD, works to develop more effective treatments for patients with multiple myeloma (MM) and understand racial disparities in outcomes.
Edward W. and Betty Knight Scripps Professor of Medicine, Mayo Clinic
Donald P. Pinkel, MD, led the development of multimodal therapy for children with acute lymphoblastic leukemia (ALL), resulting in one of the first significant cure rates for cancer.
Founding Director and CEO, St. Jude Children’s Research Hospital (retired)
Henry T. Lynch, MD, the namesake for Lynch syndrome, is known as the “father of cancer genetics” and “the father of hereditary cancer detection and prevention” for his work identifying cancer syndromes and their patterns of inheritance.
Charles F. and Mary C. Heider Endowed Chair in Cancer Research, Creighton University School of Medicine
Jamie H. Von Roenn, MD, is a leader in identifying and developing ways to integrate palliative medicine skills and principles into the care of patients with cancer.
Vice President of Education, Science, and Professional Development for the American Society of Clinical Oncology (ASCO)
Susan Band Horwitz, PhD, conducted groundbreaking research that established the mechanism of action of paclitaxel (Taxol) and other cytotoxic drugs of natural product origin.
Distinguished Professor, Rose C. Falkenstein Chair in Cancer Research, Albert Einstein College of Medicine